Price
CHART BY
Frequently asked questions
What is Penumbra's market capitalization?
The market capitalization of Penumbra is $12.97B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Penumbra's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Penumbra is 72.95. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Penumbra?
Penumbra's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $4.524. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Penumbra's stock?
Currently, 11 analysts cover Penumbra's stock, with a consensus target price of $370.38. Analyst ratings provide insights into the stock's expected performance.
What is Penumbra's revenue over the trailing twelve months?
Over the trailing twelve months, Penumbra reported a revenue of $1.40B.
What is the EBITDA for Penumbra?
Penumbra's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $206.72M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Penumbra?
Penumbra has a free cash flow of $174.93M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Penumbra have, and what sector and industry does it belong to?
Penumbra employs approximately 4,700 people. It operates in the Health Care sector, specifically within the Medical Specialties industry.
What is the free float of Penumbra's shares?
The free float of Penumbra is 38.10M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $12.97B
- EPS (TTM)
- $4.524
- Free Float
- 38.10M
- P/E ratio (TTM)
- 72.95
- Revenue (TTM)
- $1.40B
- EBITDA (TTM)
- $206.72M
- Free Cashflow (TTM)
- $174.93M
Pricing
- 1D span
- $327.90$330.65
- 52W span
- $221.28$362.39
Analyst Ratings
The price target is $370.38 and the stock is covered by 11 analysts.
Buy
1
Hold
9
Sell
1
Information
Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.
- Employees
- 4,700
- Industries
- Medical Specialties
- Sector
- Health Care
Identifier
- Primary Ticker
- PEN
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet